Semaglutide vs Dulaglutide
## Overview
Semaglutide and dulaglutide are both once-weekly SC GLP-1 receptor agonists. Dulaglutide (Trulicity) has a GLP-1 Fc fusion protein structure; semaglutide is a fatty acid-modified GLP-1 analog. The AWARD-11 trial showed semaglutide produced significantly greater HbA1c and weight reduction.
## Mechanism of Action
Both activate GLP-1 receptors. Dulaglutide's Fc fusion with albumin and modified GLP-1 sequence confers once-weekly half-life. Semaglutide's C18 fatty diacid achieves stronger albumin binding for 7-day half-life.
## Pharmacokinetics
Dulaglutide: once-weekly SC, half-life ~4.7 days, Fc-mediated clearance. Semaglutide: once-weekly SC, half-life ~7 days (stronger albumin binding).
## Clinical Comparison
AWARD-11 (head-to-head dulaglutide 3 mg/4.5 mg vs semaglutide 0.5 mg/1 mg): semaglutide 1 mg reduced HbA1c ~1.5% vs dulaglutide 1.5 mg ~1.1%. Weight loss ~6 kg vs ~3 kg. REWIND (dulaglutide): 12% MACE reduction in T2DM with CV risk. SUSTAIN-6 (semaglutide): 26% MACE reduction.
## Ease of Use
Dulaglutide's single-use pen is often cited as easier to use, with no need for reconstitution. Semaglutide pens require rotation and priming. Both once-weekly.
## Key Takeaways
- Semaglutide: greater HbA1c reduction and weight loss, superior CV data
- Dulaglutide: easier device use, well-tolerated, positive CV data (REWIND)
- Both once-weekly SC; semaglutide clinically superior in head-to-head comparisons
Sonuç
Semaglutide is preferred over dulaglutide based on superior HbA1c reduction, greater weight loss, and stronger cardiovascular outcome data. Dulaglutide is a well-tolerated alternative with a simpler injection device that may be preferred by patients who have difficulty with pen preparation.